Company Filing History:
2 out of 505 
1 out of 1 Years Active: 1995-2017
Title: Fabienne Mathieu: Innovator in Hybridoma Technology
Introduction
Fabienne Mathieu is a notable inventor based in Nivelles, Belgium. She has made significant contributions to the field of biotechnology, particularly in the development of hybridoma technology and antibody production. With a total of 3 patents to her name, her work has implications for various applications in medical science.
Latest Patents
Among her latest patents is a process for the production of a hybridoma and the monoclonal antibody derived from it, which is capable of recognizing multiple vitamin D metabolites. This invention focuses on a method to produce a hybridoma that generates a monoclonal antibody or its fragments, specifically targeting 25-hydroxyvitamin D. Another significant patent involves the creation of microspheres designed for the controlled release of water-soluble substances. These microspheres are made from a biocompatible and biodegradable polymer that is soluble in an organic solvent, which is immiscible in water. The innovative aspect of this invention is that the microspheres can release the encapsulated substance over a period of at least eight days in an aqueous physiological environment, with minimal initial release.
Career Highlights
Fabienne has worked with prominent companies in the pharmaceutical and biotechnology sectors, including Teva Pharmaceutical Industries Limited and Diasource Immunoassays S.A. Her experience in these organizations has allowed her to apply her innovative ideas in practical settings, contributing to advancements in medical technology.
Collaborations
Throughout her career, Fabienne has collaborated with esteemed colleagues such as Henri Wantier and Marc Baudrihaye. These partnerships have fostered a collaborative environment that enhances the development of her groundbreaking inventions.
Conclusion
Fabienne Mathieu stands out as a pioneering inventor in the field of hybridoma technology and antibody production. Her contributions are vital to the advancement of medical science, and her patents reflect her commitment to innovation.